Advertisement

Breast Cancer Research and Treatment

, Volume 101, Issue 2, pp 185–190 | Cite as

Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients

  • O. Markovitch
  • R. Tepper
  • A. Fishman
  • R. Aviram
  • I. Cohen
Clinical Trial

Abstract

Objective

Aromatase inhibitors may decrease endometrial thickness in breast cancer patients previously having short-term tamoxifen treatment. There is a necessity to find out if aromatase inhibitors can also decrease endometrial thickness in patients previously treated with long-term tamoxifen treatment.

Methods

Prospective comparison of the last ultrasonographic endometrial thickness measurement taken before discontinuation of long-term tamoxifen treatment in 36 postmenopausal breast cancer patients, with further measurements, performed following aromatase inhibitors administration.

Results

There was a significant decrement of endometrial thickness, following 36.2 ± 16.8 months of tamoxifen treatment, from a mean value of 9.1 ± 5.8 mm, measured at the last ultrasonographic measurement performed before discontinuation of tamoxifen treatment, down to a mean value of 6.0 ± 5.0 mm, measured following 5.8 ± 5.8 months of aromatase inhibitors therapy (P = 0.001). A second ultrasonographic measurement performed in 8 patients following of additional 7.5 ± 4.0 months of aromatase inhibitors treatment revealed further decrement of mean endometrial thickness to 4.8 ± 2.1 mm (P = 0.002 compared to baseline).

In 28 patients (77.8%), endometrial thickness was reduced following the administration of aromatase inhibitors, in four patients (11.1%) there was no change in endometrial thickness and four (11.1%) patients demonstrated an increase of endometrial thickness.

Conclusions

Aromatase inhibitors may reverse endometrial thickening induced by long-term tamoxifen treatment in postmenopausal breast cancer patients.

Keywords

Endometrial thickness Aromatase inhibitors Tamoxifen Ultrasound 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgment

We thank Mrs. Marilyn Benson for her editorial assistance.

References

  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–71Google Scholar
  2. 2.
    Cohen I, Rosen DJD, Shapira J, et al (1993) Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100:567–570PubMedGoogle Scholar
  3. 3.
    Lahti E, Blanco G, Kauppila A, et al (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660–664PubMedGoogle Scholar
  4. 4.
    Cohen I, Rosen DJD, Tepper R, et al (1993) Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 5:275–280Google Scholar
  5. 5.
    Hulka CA, Hall DA (1993) Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. AJR 160:809–812PubMedGoogle Scholar
  6. 6.
    Cohen I, Rosen DJD, Shapira J, et al (1994) Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185–190PubMedCrossRefGoogle Scholar
  7. 7.
    Exacoustos C, Zupi E, Cangi B, et al (1995) Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound colour flow Doppler, hysteroscopic and histologic study. Ultrasound Obstet Gynecol 6:435–442PubMedCrossRefGoogle Scholar
  8. 8.
    Cecchini S, Ciatto S, Bonardi R, et al (1996) Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol 60:409–411PubMedCrossRefGoogle Scholar
  9. 9.
    Hann LE, Geiss CS, Bach AM, et al (1997) Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings. AJR 168:657–661PubMedGoogle Scholar
  10. 10.
    Timmerman D, Deprest J, Bourne T, et al (1998) Randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 179:62–70PubMedCrossRefGoogle Scholar
  11. 11.
    Bertelli G, Venturini M, Del Mastro L, et al (1998) Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47:41–46PubMedCrossRefGoogle Scholar
  12. 12.
    Love CDB, Muir BB, Scrimgeour JB, et al (1999) Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17: 2050–2054PubMedGoogle Scholar
  13. 13.
    Mourits MJE, Van der Zee AGJ, Willemse PHB, et al (1999) Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 73:21–26PubMedCrossRefGoogle Scholar
  14. 14.
    Tesoro MR, Borgida AF, MacLaurin NA, et al (1999) Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 93:363–366PubMedCrossRefGoogle Scholar
  15. 15.
    Gerber B, Krause A, Muller H, et al (2000) Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 18:3464–3470PubMedGoogle Scholar
  16. 16.
    Hann LE, Gretz EM, Bach AM, et al (2001) Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. AJR 177:337–342PubMedGoogle Scholar
  17. 17.
    Fong K, Kung R, Lytwyn A, et al (2001) Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 220:765–773PubMedCrossRefGoogle Scholar
  18. 18.
    Ciato S, Cecchini S, Bonardi R, et al (1994) Ultrasonographic surveillance of endometrium in breast cancer patients on adjuvant tamoxifen. Lancet 244:260Google Scholar
  19. 19.
    Goldstein SR (1994) Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170:447–451PubMedGoogle Scholar
  20. 20.
    Franchi M, Ghezzi F, Donadello N, et al (1999) Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 93:1004–1008PubMedCrossRefGoogle Scholar
  21. 21.
    Nahari K, Tepper R, Beyth Y, et al (1999) Long-term transvaginal endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol 74:222–226PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen I, Beyth Y, Azaria R, et al (2000) Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Brit J Obstet Gynecol 107:1083–1087Google Scholar
  23. 23.
    Decensi A, Fontana V, Bruno S, et al (1996) Effect of tamoxifen on endometrial proliferation. J Clin Oncol 14: 434–440PubMedGoogle Scholar
  24. 24.
    Cohen I, Azaria R, Shapira J, et al (2002) Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 94:3101–3106PubMedCrossRefGoogle Scholar
  25. 25.
    Markovitz O, Tepper R, Fishman A, et al (2004) The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 95:456–462CrossRefGoogle Scholar
  26. 26.
    Menada MV, Papadia A, Lorenzi P, et al (2004) Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaec Oncol 25:321–323Google Scholar
  27. 27.
    Fishman M, Boda M, Sheiner E, et al (2006) Chnages in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. J Ultrasound Med 25:469–473PubMedGoogle Scholar
  28. 28.
    The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131–2139CrossRefGoogle Scholar
  29. 29.
    Goss P, Ingle J, Martino S (2003) A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1–10CrossRefGoogle Scholar
  30. 30.
    Duffy S, Jackson TL, Lansdown M, et al (2006) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Human Reprod 21:545–553CrossRefGoogle Scholar
  31. 31.
    Garrone O, Mezi S, Occelli M, Ortu B, Favilla A, Schere L, Bertolotti P, Rizzo A, Rinaldi M, Merlano N, Crosseto N, et al (2003) Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients A prospective transvaginal ultrasound study (TVUS). Ann Oncol 14 (Suppl 4):iv7 (Abstr A22)Google Scholar
  32. 32.
    Morales L, Timmerman D, Neven P, et al (2005) Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16:70–74PubMedCrossRefGoogle Scholar
  33. 33.
    Berliere M, Galant C, Charles A, et al (2002) Endometrial evaluation is a very important tool in the management of breast cancer patients. Eur J Cancer (Suppl) 6:S67–S68Google Scholar
  34. 34.
    Hachisuga T, Saito T, Kigawa J, et al (2004) Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for breast cancers. Gynecol Oncol 95:139–144PubMedCrossRefGoogle Scholar
  35. 35.
    Ferguson SE, Solow RA, Amsterdam A, et al (2006) Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 101:322--326Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • O. Markovitch
    • 1
    • 2
  • R. Tepper
    • 1
    • 2
  • A. Fishman
    • 1
  • R. Aviram
    • 1
    • 2
  • I. Cohen
    • 1
  1. 1.Department of Obstetrics and GynecologyMeir Medical Center, Sackler Faculty of Medicine, Tel Aviv UniversityKfar-SabaIsrael
  2. 2.Gynecological Ultrasound UnitMeir Medical CenterKfar-SabaIsrael

Personalised recommendations